Cresco Labs Inc. (OTCMKTS:CRLBF - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.50.
CRLBF has been the topic of a number of recent analyst reports. Roth Capital raised Cresco Labs to a "strong-buy" rating in a report on Sunday, November 10th. Cormark cut shares of Cresco Labs from a "moderate buy" rating to a "hold" rating in a research note on Monday, November 11th. Finally, Atb Cap Markets cut shares of Cresco Labs from a "strong-buy" rating to a "hold" rating in a research note on Monday.
Get Our Latest Analysis on CRLBF
Cresco Labs Stock Performance
OTCMKTS:CRLBF traded up $0.03 during mid-day trading on Friday, reaching $1.00. The stock had a trading volume of 1,115,360 shares, compared to its average volume of 757,770. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The business has a 50 day simple moving average of $1.37 and a 200 day simple moving average of $1.57. Cresco Labs has a twelve month low of $0.96 and a twelve month high of $2.65. The firm has a market capitalization of $488.14 million, a price-to-earnings ratio of -4.88 and a beta of 1.73.
About Cresco Labs
(
Get Free ReportCresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Featured Stories
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.